for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AC Immune SA

ACIU.OQ

Latest Trade

7.42USD

Change

-0.02(-0.27%)

Volume

4,542

Today's Range

7.42

 - 

7.50

52 Week Range

3.25

 - 

12.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.44
Open
7.49
Volume
4,542
3M AVG Volume
2.06
Today's High
7.50
Today's Low
7.42
52 Week High
12.50
52 Week Low
3.25
Shares Out (MIL)
67.56
Market Cap (MIL)
527.66
Forward P/E
9.21
Dividend (Yield %)
--

Next Event

AC Immune SA at Jefferies London Healthcare Conference

Latest Developments

More

AC Immune Receives First Milestone Payment From Lilly In Small Molecule Tau Morphomer Program

Ac Immune SA - QTRLY Adjusted Loss Per Share $0.22

AC Immune Says Douglas Williams Elected As Chairman

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AC Immune SA

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Industry

Biotechnology & Drugs

Contact Info

EPFL Innovation Park, Building B

+41.21.3459121

https://www.acimmune.com/

Executive Leadership

Douglas E. Williams

Chairman of the Board

Andrea Pfeifer

Chief Executive Officer, Director

Martin Velasco

Independent Vice Chairman of the Board

Joerg Hornstein

Chief Financial Officer

Jean-Fabien Monin

Chief Administrative Officer

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (CHF)

2016

-0.140

2017

-0.460

2018

-0.820

2019(E)

0.840
Price To Earnings (TTM)
10.57
Price To Sales (TTM)
4.69
Price To Book (MRQ)
1.79
Price To Cash Flow (TTM)
10.11
Total Debt To Equity (MRQ)
0.86
LT Debt To Equity (MRQ)
0.60
Return on Investment (TTM)
20.11
Return on Equity (TTM)
19.16

Latest News

Latest News

Roche, AC Immune drop Alzheimer drug trials after setback

Roche Holding and partner AC Immune SA called a halt to two late-stage clinical trials of their crenezumab drug for early Alzheimer's, the latest in a string of failures to find a treatment for the progressive brain disease.

Lilly partners with AC Immune for Alzheimer's treatment

U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease.

Lilly partners with AC Immune for Alzheimer's treatment

Eli Lilly & Co and AC Immune SA have agreed to jointly develop a potential treatment for Alzheimer's disease.

BRIEF-AC Immune Says Co's Selling Shareholder May Sell Up To 18 Mln Common Shares

* AC IMMUNE SAYS CO'S SELLING SHAREHOLDER MAY SELL UP TO 18 MILLION COMMON SHARES Source text: (https://bit.ly/2P0dXMm) Further company coverage:

BRIEF-AC Immune SA reports quarterly ‍loss per share CHF 0.15

* AC Immune SA reports third quarter 2017 financial results and corporate update

BRIEF-AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease

* AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease

BRIEF-AC Immune to get milestone payment for Alzheimer drug

* Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease

BRIEF-AC Immune to present at two investor conferences and provide scientific updates at CTAD conference

* AC Immune to present at two investor conferences and provide scientific updates at CTAD conference Source text for Eikon: Further company coverage:

BRIEF-AC Immune completes recruitment for low-dose cohort in world's first clinical trial for Anti-Abeta Vaccine

* AC Immune completes recruitment for low-dose Cohort in world's first clinical trial for Anti-Abeta Vaccine targeting alzheimer's disease-like characteristics in individuals with down syndrome Source text for Eikon: Further company coverage:

BRIEF-AC Immune reports Q2 ‍loss per share CHF 0.22​

* Q2 earnings per share view chf -0.16 -- Thomson Reuters I/B/E/S

BRIEF-AC Immune SA reports qtrly loss per share CHF 0.17

* Qtrly total revenues CHF 2.0 million versus. CHF 0.5 million Source text for Eikon: Further company coverage:

BRIEF-AC Immune generated revenue of chf 23.2 mln in twelve months ended Dec. 31, vs chf 39.1 mln

* Ac immune reports full year 2016 financial results and research and development update

BRIEF-AC Immune partner Genentech to start second Phase 3 clinical trial for Alzheimer's therapy Crenezumab

* Ac immune partner genentech to start second phase 3 clinical trial for alzheimer's therapy crenezumab

BRIEF-AC Immune appoints Joerg Hornstein as chief financial officer

* Hornstein replaces George Pavey, who is leaving company after its recent successful IPO

BRIEF-AC Immune names Hornstein as CFO as of Q1 2017

* Says names Joerg Hornstein as chief financial officer effective Q1 2017

BRIEF-Temasek Holdings takes stake in AC Immune, Ctrip.com

* Temasek Holdings - holds share stake of 21.2 million shares in IHS Markit Ltd

BRIEF-Ac Immune reports Q3 results

* Ac Immune for three months period ended sept 30, 2016, had net loss after taxes of chf 9.1 million compared with CHF 20.1 million profit for same period in 2015

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up